Clinical Trial Update: The Impact of Delflex on Mesothelial Cell Viability and Peritoneal Transport [NA]

View source ↗

Summary

The clinical trial evaluating Delflex for end-stage renal disease, focusing on mesothelial cell viability and peritoneal transport, has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Renal Disease

Drugs mentioned

• DELFLEX (DEXTROSE MONOHYDRATE, SODIUM CHLORIDE, SODIUM LACTATE, CALCIUM CHLORIDE, MAGNESIUM CHLORIDE)

Snippet

Sponsor: University of North Carolina, Chapel Hill | Conditions: End Stage Renal Disease | NA | Status: WITHDRAWN